This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: DESTINY-Breast06 Trial - HER2-Low and HER2-Ultralow Status Determination in Tumors of Patients With HR+ mBC

323 views
September 23, 2024
Comments 0
Login to view comments. Click here to Login